BioSpace News Archive

Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA) reported second quarter 2023 financial results and business highlights.

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced its operating and financial results for the quarter ended June 30, 2023.

Codexis, Inc., a leading enzyme engineering company, announced the launch of a new mini documentary as part of an ongoing campaign in support of World Health Day.

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets.

Immutep Limited today announces that data from its TACTI-002 Phase II trial evaluating the chemo-free combination of eftilagimod alpha (“efti”) and KEYTRUDA® (pembrolizumab), MSD’s (Merck & Co., Rahway, NJ, USA) anti-PD-1 therapy, in 1st line non-small cell lung cancer (1L NSCLC) has been accepted for a Mini Oral presentation at the 2023 European Society for Medical Oncology (ESMO) Congress that will be held in Madrid, Spain from 20-24 October 2023.

OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

DSS, Inc. announced today the distribution date for the previously announced stock dividend of Impact BioMedical Inc. DSS Inc. shareholders of record on July 10, 2023 will be entitled to four (4) shares of Impact Biomedical Inc. for every one (1) share of DSS to be distributed on August 8, 2023.

COMPASS Pathways plc, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023.

Smirta is pleased to announce that OneOncology has selected Smirta as a preferred vendor to provide Smirta’s OncoSmart® oncology infusion schedule optimization platform to the OneOncology network of physician practices.

G1 Therapeutics, Inc. (Nasdaq: GTHX) today announced the publication of real world outcomes data from published and new unpublished studies showing the potential of trilaciclib to reduce single and multilineage myelosuppressive events associated with chemotherapy, cytopenia-related healthcare utilization, and hospitalizations in adults being treated for extensive stage small cell lung cancer (ES-SCLC).